Mobile health monitoring in the management of long term conditions has potential benefits for patient care, especially when coupled with active adjustment of medication dosage. We report studies of patient-led self-titration of oral glucose lowering medication (OGLM) and insulin in type 2 diabetes, and dose adjustments (including dose increases) in oral chemotherapy for metastatic colorectal or breast cancer. Monitoring compliance was high in each case, and the feasibility of patients self-titrating OGLM or insulin following an agreed treatment plan was demonstrated. Chemotherapy dose increases supported by detailed toxicity profiles collected by phone have also been demonstrated.

Original publication

DOI

10.1109/iembs.2011.6090449

Type

Journal article

Journal

Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference

Publication Date

01/2011

Volume

2011

Pages

1540 - 1543

Addresses

Department of Engineering Science, Institute of Biomedical Engineering, University of Oxford, Oxford OX3 7DQ, UK. mel@robots.ox.ac.uk

Keywords

Humans, Neoplasms, Diabetes Mellitus, Type 2, Fluorouracil, Insulin, Deoxycytidine, Antimetabolites, Antineoplastic, Hypoglycemic Agents, Blood Glucose Self-Monitoring, Treatment Outcome, Drug Therapy, Computer-Assisted, Administration, Oral, Telemedicine, Dose-Response Relationship, Drug, Female